Syncona Limited Directorate Change

 
TIDMSYNC 
 
8 September 2017 
 
 
                                Syncona Limited 
                Legal Entity Identifier - 213800X8MBI5VQITLW60 
 
                              Directorate Change 
 
The Company announces the resignation of Peter Hames as a non-executive 
director of the Company, effective as of the completion of the Company's Annual 
General Meeting today, 8 September 2017.  Mr. Hames has been a Board member 
since the Company listed in 2012, and the Company wishes to thank him for his 
invaluable contribution. 
 
 
[ENDS] 
 
Enquiries 
 
Northern Trust International Fund Administration Services (Guernsey) Limited 
Company Secretary 
Tel:       [phone] 
 
Copies of this announcement and other corporate information can be found on the 
company website at:www.synconaltd.com 
 
About Syncona: 
 
Syncona is a leading FTSE250 healthcare company focused on investing in and 
building global leaders in life science. Our vision is to deliver 
transformational treatments to patients in truly innovative areas of healthcare 
while generating superior returns for shareholders. Our current investment 
portfolio consists of seven high quality companies in life science and a 
leading range of fund investments. 
 
We seek to partner with the best, brightest and most ambitious minds in science 
to build globally competitive businesses. We are established leaders in gene 
therapy, cell therapy and advanced diagnostics, and focus on delivering 
dramatic efficacy for patients in areas of high unmet need. 
 
Our market leading funds portfolio seeks to generate superior returns by 
investing in long only and alternative investment funds. This represents a 
productively deployed evergreen funding base which enables us to take a long 
term approach to investing in life sciences as we target the best new 
opportunities and support our existing portfolio companies to grow and succeed. 
 
Syncona is aligned with two of the premium charitable funders in UK science, 
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both 
of which are significant shareholders in our business.  We make a donation of 
0.3% of Net Asset Value to a range of charities each year. 
 
 
 
END 
 

(END) Dow Jones Newswires

September 08, 2017 11:39 ET (15:39 GMT)